US10806X1028
© Globe Newswire
16.01.2026
BBIO
LISTED
NASDAQ
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
News Preview
PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a new type of biopharmaceutical company focused on genetic diseases, announced today the pricing of $550 million aggregate principal amount of 0.75% convertible senior notes due 2033 (the “notes”) in a private offering...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
BBIO
LISTED
NASDAQ
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
News Preview
-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
BBIO
LISTED
NASDAQ
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
- Preliminary unaudited Q4 and Full Year 2025 net Attruby® product revenue of $146.0 million and $362.4 million, respectively...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
05.01.2026
BBIO
LISTED
NASDAQ
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
News Preview
PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
02.01.2026
BBIO
LISTED
NASDAQ
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
News Preview
PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET with Janet Legare, M.D., Professor in the Divisions of Ge...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.12.2025
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on December 18, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 9 new employees in restric...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
BBIO
LISTED
NASDAQ
BridgeBio to Participate in December Investor Conferences
News Preview
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.11.2025
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on November 17, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 12 new employees in restri...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2025
BBIO
LISTED
NASDAQ
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
News Preview
- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
BBIO
LISTED
NASDAQ
BridgeBio to Participate in November Investor Conferences
News Preview
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
BBIO
LISTED
NASDAQ
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
News Preview
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orle...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
BBIO
LISTED
NASDAQ
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
News Preview
- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
24.10.2025
BBIO
LISTED
NASDAQ
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
News Preview
PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate business update calls to share the following:...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on October 2, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 11 new employees in restrict...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.09.2025
BBIO
LISTED
NASDAQ
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
News Preview
- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
BBIO
LISTED
NASDAQ
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
News Preview
PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clinical trials oral presentation, one oral presentation, and three poster sessions will be shared at the Heart Fail...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that the compensation committee of its board of directors (the “committee”) approved equity grants in the form of restricted stock units (“...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.09.2025
BBIO
LISTED
NASDAQ
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
News Preview
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therapy at baseline...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
BBIO
LISTED
NASDAQ
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
News Preview
PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
BBIO
LISTED
NASDAQ
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
News Preview
PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be sh...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2025
BBIO
LISTED
NASDAQ
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension
News Preview
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
BBIO
LISTED
NASDAQ
BridgeBio to Participate in September Investor Conferences
News Preview
PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
BBIO
LISTED
NASDAQ
BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
News Preview
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label extension data from ATTRibute-CM and two ePosters with ATTRibute-CM data at M...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
BBIO
LISTED
NASDAQ
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
News Preview
- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with acoramidis, a near-complete (≥90%) TTR stabilizer, lead to ever better clinical outcomes...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.04.2025
BBIO
LISTED
NASDAQ
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
News Preview
- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.04.2025
BBIO
LISTED
NASDAQ
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
News Preview
- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.03.2025
BBIO
LISTED
NASDAQ
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
News Preview
PALO ALTO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time to all-cause mortality (ACM) or...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.03.2025
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
PALO ALTO, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on March 19, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 10 new employees in res...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.02.2025
BBIO
LISTED
NASDAQ
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
News Preview
PALO ALTO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate principal amount of 1.75% convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 14...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
BBIO
LISTED
NASDAQ
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
News Preview
- Long term debt management strategy will strengthen the balance sheet without increasing total liabilities...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
News Preview
- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.02.2025
BBIO
LISTED
NASDAQ
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
News Preview
PALO ALTO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the European Commission has granted marketing authorization in the European Union (EU) for acoramidis, under the brand name BEYONTTRA™, for...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
BBIO
LISTED
NASDAQ
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
News Preview
- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.12.2024
BBIO
LISTED
NASDAQ
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
News Preview
PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization in the Eu...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.11.2024
BBIO
LISTED
NASDAQ
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
News Preview
- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2024
BBIO
LISTED
NASDAQ
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
News Preview
- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2024
BBIO
LISTED
NASDAQ
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
News Preview
- In Cohort 5 of PROPEL 2, daily oral treatment of infigratinib at 0.25mg/kg resulted in statistically significant and sustained increases in annualized height velocity (AHV), with a mean change from baseline of +2.50cm/year at Month 18 (P=0.001)...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.09.2024
BBIO
LISTED
NASDAQ
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
News Preview
- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2024
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
News Preview
- Increase in endogenous cortisol production achieved in all patients in higher dose cohorts of BBP-631, a result seen for the first time ever in CAH patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2024
BBIO
LISTED
NASDAQ
BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
News Preview
- Receipt of RMAT Designation is based on preliminary clinical evidence from the CANaspire Phase 1/2 clinical trial, which showed functional improvements in all dosed patients indicating that BBP-812 has potential to address the unmet needs of individuals with Canavan disease...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.09.2024
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
PALO ALTO, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on September 4, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 123 new employees in...
Themefolio
Profiler
Peergroup
© BusinessWire
30.08.2024
BBIO
LISTED
NASDAQ
BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIO
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”). KSF is investigating whether BridgeBio’s board of directors breached their fiduciary duties in connection with...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
BBIO
LISTED
NASDAQ
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
News Preview
- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum transthyretin (TTR) at Month 1 of the OLE (n=21) and mean of 3.4mg/dL increase in serum TTR at Month 6 of the OLE (n=18)...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2024
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
News Preview
PALO ALTO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases, today reported its financial results for the second quarter ended June 30, 2024, and provided an update on the Company’s operations....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.07.2024
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on July 2, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 25 new employees in restri...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
News Preview
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for pr...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
